January 11, 2026 a 08:38 pm
KVUE: Analysts Ratings - Kenvue Inc.
Kenvue Inc., a subsidiary of Johnson & Johnson, operates in the consumer health sector with diverse products across self-care, skin health, and essential health segments. As of early 2026, the company's stock is primarily rated as 'Hold' by analysts. Monitoring of sentiment trends reveals fluctuations in buy and hold ratings, suggesting cautious optimism in the market.
Historical Stock Grades
The latest analyst ratings for Kenvue as of January 1, 2026, show a prevalent sentiment towards holding the stock. Despite a minor presence of stronger buy signals, the overall analyst community indicates neutrality with recommendations to hold.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 2 | |
| Hold | 11 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, Kenvue's stock has seen a consistency in 'Hold' ratings with minor fluctuations in 'Buy' and 'Strong Buy' categories. Key observations include:
- The total number of ratings has become steadier, indicating a settled analyst consensus.
- A noticeable decline in 'Buy' recommendations from previous highs, aligning with a more conservative market outlook.
- Hold ratings have solidified, reflecting the market's caution but lack of inclination towards sell signals.
Percentage Trends
Percentage analysis highlights the shift from aggressive buying to holding recommendations. Over the last year, we've seen:
- 'Strong Buy' decreased from 16% to 6%, signifying more conservative strategies.
- 'Buy' initially peaked at 33% but has dropped to 11%, mirroring investors' caution.
- 'Hold' increased from 50% to 83%, suggesting stability in outlook but limited upside enthusiasm.
- 'Sell' and 'Strong Sell' remain negligible, reinforcing the absence of a negative outlook.
- Key fluctuations occurred predominantly in the first quarter of 2025.
Latest Analyst Recommendations
Recent analyst recommendations depict a trend of maintained positions, with some downgrades from 'Buy' to 'Hold'. Details are as follows:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-10 | Equal Weight | Equal Weight | Barclays |
| 2025-10-29 | Hold | Buy | Canaccord Genuity |
| 2025-10-27 | Buy | Buy | Jefferies |
| 2025-10-10 | Overweight | Overweight | JP Morgan |
| 2025-10-09 | Neutral | Neutral | Citigroup |
Analyst Recommendations with Change of Opinion
The analysts exhibit shifts in sentiment, with notable downgrades and upgrades over the past few months, reflecting changing market perceptions about Kenvue. Key observations include:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-29 | Hold | Buy | Canaccord Genuity |
| 2025-09-26 | Buy | Neutral | Rothschild & Co |
| 2025-01-06 | Overweight | Neutral | Piper Sandler |
| 2024-12-12 | Hold | Buy | Deutsche Bank |
| 2024-09-24 | Sector Perform | Outperform | RBC Capital |
Interpretation
The consensus of 'Hold' ratings suggests that analysts see Kenvue's stock as fairly valued, with minimal enthusiasm for strong buys. Notable downgrades in recent months indicate an environment of increased caution and stability rather than buoyant optimism. The recent trend towards holding implies underlying confidence in the company's resilience, though significant upside is not anticipated. Analysts appear content with current valuations, hesitating from aggressive guidance either towards buy or sell.
Conclusion
Kenvue Inc.'s stock analysis over the past year illustrates a shift towards conservatism within analyst recommendations, with a dominant stance on holding. The move away from buy signals toward hold indicates a wait-and-see approach amid market uncertainties. However, the lack of sell signals reflects confidence in the company's fundamentals. Investors should consider this stock as stable but without immediate high-growth potential, while remaining attuned to future quarterly performances and strategic initiatives that may alter this sentiment landscape.